Industry News

on 'Clinical Trials'

1-7 of 7 < first | prev | next | last >
  • EIP Pharma closes financing for new indications for former Vertex drug

    EIP Pharma, a central nervous system-focused therapeutics company, announced the successful completion of $11.2 million in new private funding to explore the use of an investigational drug as a treatment for dementia with Lewy bodies and for the cognitive deficits in Huntington's disease.

  • ViiV HIV shot passes late-stage trials

    ViiV Healthcare has announced that its once-a-month shot, designed as an alternative to daily doses of HIV treatment drugs, has met primary endpoints in a pair of pivotal phase III studies.

  • Narcan-maker Opiant abandons bulimia drug

    Opiant Pharmaceuticals, a specialty pharmaceutical company developing medicines for addictions and drug overdose, has halted its trial for a nasal spray designed to treat bulimia nervosa.

  • AstraZeneca appoints controversial R&D leader

    AstraZeneca has appointed well-known but controversial cancer doctor, José Baselga, to head research and development for oncology, as part of a larger overhaul designed to speed drugs to market

  • Innovent drops $40M on Incyte drugs in China

    Innovent Biologics and Incyte have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Delaware-based Incyte.

1-7 of 7 < first | prev | next | last >